Cargando…
Characterization of a whole, inactivated influenza (H5N1) vaccine
Objectives Effective vaccines against the highly pathogenic influenza A/H5N1 virus are being developed worldwide. In Japan, two adjuvanted, inactivated, whole‐virion influenza vaccines were recently developed and licensed as mock‐up, pre‐pandemic vaccine formulations by the Ministry of Health and L...
Autor principal: | Tada, Yoshikazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634112/ https://www.ncbi.nlm.nih.gov/pubmed/19453403 http://dx.doi.org/10.1111/j.1750-2659.2008.00066.x |
Ejemplares similares
-
Inactivated Whole Virus Influenza A (H5N1) Vaccine
por: Vajo, Zoltan, et al.
Publicado: (2007) -
Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine
por: Zhang, Zhegang, et al.
Publicado: (2022) -
Preservation of the Immunogenicity of Dry-powder Influenza H5N1 Whole Inactivated Virus Vaccine at Elevated Storage Temperatures
por: Geeraedts, Felix, et al.
Publicado: (2010) -
A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice
por: Hovden, Arnt‐Ove, et al.
Publicado: (2009) -
Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling
por: Geeraedts, Felix, et al.
Publicado: (2008)